ADA: Insulin Delivery Systems Compared in Type 1 Diabetes

WEDNESDAY, June 8, 2022 (HealthDay News) -- An open-source automated insulin delivery (AID) system appears to be safe and effective for use in people with type 1 diabetes, according to a study presented at the annual meeting of the American Diabetes Association, held from June 3 to 7 in New Orleans.

Mercedes J. Burnside, from the University of Otago in Christchurch, New Zealand, and colleagues examined the efficacy and safety of open-source AID. Forty-eight children (ages 7 to 15 years) and 49 adults (16 to 70 years) with type 1 diabetes were randomly assigned to either open-source AID (using the OpenAPS algorithm from a version of AndroidAPS implemented in a smartphone with the DANA-i insulin pump and Dexcom G6 continuous glucose monitor) or sensor augmented pump therapy (SAPT).

The researchers found that mean time in target sensor glucose range (TIR) at study end was 74.5 percent using AID for adults and 67.5 percent for children. For the SAPT arm, the mean TIR at study end was 56.5 percent for adults and 52.5 percent for children. Neither group experienced severe hypoglycemic or diabetic ketoacidosis events. Two participants withdrew from AID due to hardware issues.

"While open-source AID is not yet approved by the Food and Drug Administration, we know people worldwide are using it to manage their diabetes," lead author Martin de Bock, Ph.D., also from the University of Otago, said in a statement. "Our findings demonstrate that this is a safe and effective technology and adds to the body of evidence supporting use of open-source AID for improving glycemic outcomes."

Several authors disclosed financial ties to the pharmaceutical industry.

Press Release

More Information